The annual Conference on Retroviruses and Opportunistic Infections (CROI) was held on 4-7 March 2019, at the Washington State Convention Center in Seattle, Washington. At this year’s event, EPIICAL team member Sara Dominguez Rodriguez delivered an engaging oral presentation on the earliest antiretroviral therapy initiation in infants.
Seattle is gearing up for the 2019 edition of CROI next week. Held at Washington State Convention Center on 4th-7th March, the Conference on Retroviruses and Opportunistic Infections is an important event in the Penta calendar, and in particular for the EPIICAL consortium, as it is an opportunity for members to discuss the latest developments pertaining to the project. Included on the agenda, EPIICAL project researchers will make an oral presentation illustrating recent results that provide further evidence that supports the earliest ART initiation in infants.
Held at the Hospital General Universitario Gregorio Marañón on 14th to 16th November 2018, the 2nd EPIICAL General Assembly welcomed around 50 scientists and healthcare professionals working together to establish new scientific efforts leading to HIV remission in children.
It is with great pleasure that we announce that the first patient in the EARTH study has been recruited. This encouraging news comes to us from the PHRU site in Soweto, South Africa. Now that all sites are open for recruitment, with some patients having already been screened, we are confident we will see more participants in the near future. This is the first of 150 children to be enrolled from one of 5 sites situated in South Africa and Mozambique. The EARTH project, nested within the EPIICAL platform, is a prospective multicentre, low-interventional study of HIV+ perinatally […]
Dr. Sarah Watters takes time out of her research to give us a fascinating peek into the world of viruses.
Between the 1st and 16th February 2018, a trio of researchers from the EPIICAL platform; Dr. Eleni Nastuoli, Dr. Alfredo Tagarro and Dr. Sarah Watters, visited the five sites prior to study initiation.
We are happy to announce that the enrollment into the CARMA study is moving fast with 31 patients enrolled out of a target of 40 patients.